A Director at Quidel Corp (QDEL) is Selling Shares


Yesterday, a Director at Quidel Corp (QDEL), Mary Lake Polan, sold shares of QDEL for $896.8K.

Following Mary Lake Polan’s last QDEL Sell transaction on February 07, 2019, the stock climbed by 11.1%.

See today’s analyst top recommended stocks >>

Based on Quidel Corp’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $133 million and quarterly net profit of $32.48 million. In comparison, last year the company earned revenue of $115 million and had a GAAP net loss of $5.09 million. QDEL’s market cap is $2.67B and the company has a P/E ratio of 37.04. Currently, Quidel Corp has an average volume of 438.1K.

Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $70.40, reflecting a 4.0% upside.

In the last 30 days, insiders have sold $896.8K worth of QDEL shares and purchased $112.6K worth of QDEL shares. The insider sentiment on Quidel Corp has been neutral according to 92 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Quidel Corp. engages in the development, manufacture, and market of rapid diagnostic testing solutions. Its portfolio includes immunoassays, molecular diagnostics, virology, and specialty products. Immunoassay tests are for physician offices, hospital laboratories, emergency departments, pharmacies, and other urgent care or alternative site settings.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts